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Abstract
Aims/hypothesis Familial partial lipodystrophy (FPLD) is a
rare metabolic disorder with clinical features that may not
be readily recognised. As FPLD patients require a specific
therapeutic approach, early identification is warranted. In
the present study we aimed to identify cases of FPLD
among non-obese patients with type 2 diabetes mellitus and
marked insulin resistance.
Methods We searched the databases of three diabetic
outpatient clinics for patients with marked insulin resis-
tance, arbitrarily defined as the use of ≥100 U insulin/day,
and BMI ≤27 kg/m
2. In all patients, metabolic variables
and anthropomorphic measurements were evaluated and
DNA was sequenced for mutations in the genes encoding
lamin A/C (LMNA), peroxisome proliferator-activated
receptor γ (PPARγ) and cell death-inducing DFFA-like
effector c (CIDEC).
Results Out of 5,221 diabetic individuals, 24 patients
fulfilled all criteria. Twelve patients were willing to
participate, of whom five showed clinical features of
lipodystrophy. In three of these patients the clinical
diagnosis of FPLD was confirmed by the presence of
mutations in LMNA or PPARG; one patient harboured a
novel heterozygous mutation (Y151C) in PPARG. The
Y151C mutant displayed impaired DNA-binding capacity
and hence reduced transcriptional activity compared with
wild-type PPARγ. Dominant-negative activity was absent.
Conclusion/interpretation The combination of BMI
≤27 kg/m
2 and the use of >100 U insulin/day increases the
chance of identifying lipodystrophy. Thus careful assessment
of clinical features of FPLD should be considered in these
patients, allowing earlier therapeutic interventions.
Keywords BMI.FPLD.Insulin resistance.
Lipodystrophy.LMNA.PPARγ.Type 2 diabetes mellitus.
Y151C
List of abbreviations
CIDEC Cell death-inducing DFFA-like effector c
DBD DNA-binding domain
FPLD Familial partial lipodystrophy
PPARγ Peroxisome proliferator-activated receptor -γ
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Familial partial lipodystrophy (FPLD) is an autosomal
dominant disorder characterised by abnormal distribution
of subcutaneous fat accompanied by a variable degree of
metabolic derangements, including marked insulin resis-
tance and severe hypertriacylglycerolaemia, with recurrent
episodes of pancreatitis. FPLD is a heterogeneous disorder
and diagnosis is predominantly based on clinical features.
A number of genetic defects underlying these clinical
entities have been described, but the majority of mutations
are rare coding-sequence variants in either LMNA or in
PPARG [1–3].
Although the exact numbers for estimation of prevalence
are lacking, FPLD has always been considered to be rare.
But whereas generalised lipodystrophies can be readily
detected because of the characteristic features from birth
onwards, lipodystrophy in FPLD may be overlooked
because of the overlap of clinical phenotype with the more
common presentation of type 2 diabetes mellitus.
The identification of FPLD patients carries distinct
therapeutic consequences. Patients with FPLD require
intensive measures to prevent pancreatitis and early
cardiovascular disease and may benefit from leptin-
replacement therapy [4]. Furthermore, identification of
FPLD patients may lead to the discovery of novel causative
genes that may lead to new treatment targets and improve
our understanding of the physiological mechanisms under-
lying lipodystrophy.
In the present study we aimed to identify novel cases of
FPLD in non-obese patients (BMI ≤27 kg/m
2) with type 2
diabetes mellitus and marked insulin resistance, arbitrarily
defined as total insulin dose ≥100 U/day.
Methods
In the databases of three diabetic outpatient clinics (n=
5,221) we searched for patients >18 years old with type 2
diabetes mellitus, a normal to moderately elevated BMI
(≤27 kg/m
2) and marked insulin resistance, defined as the
use of insulin ≥100 U/day. Medical records from patients
selected from the databases were first screened for
eligibility. Patients unable to visit the study centre because
of a poor medical condition as well as patients with any
other explanation for severe insulin resistance (e.g. patients
with HIV-induced lipodystrophy) were excluded from the
study. Patients fulfilling all inclusion and exclusion criteria
were invited to our research clinic. Here, the participant’s
complete medical history was evaluated and fasting blood
samples were drawn for biochemical analysis and DNA
extraction. All participants underwent a complete physical
examination with careful assessment of the presence of
FPLD stigmata. Upper arm fat was assessed by skinfold
thickness measurement and interpreted using normal
ranges, adjusting for age and sex [5]. The combination
of marked insulin resistance together with skinfold
thickness <10th percentile was considered to be compat-
ible with the phenotypical diagnosis of lipodystrophy [6].
The study was approved by the institutional review
board of the Academic Medical Centre in Amsterdam,
the Netherlands. All participants gave written informed
consent.
Genomic DNA was isolated from blood samples con-
taining EDTA. The coding exons of PPARG, CIDEC and
LMNA (exon 8–9) plus intron–exon boundaries were
sequenced using a BigDye Terminator v 1.1 cycle sequenc-
ing kit (Applied Biosystems, Foster City, CA, USA) on an
ABI Prism 3730 DNA analyser (Applied Biosystems).
Primer sequences are available upon request. Functional
analysis of the novel variant was performed as described
previously by our group [7] (for details, see data presented
as electronic supplementary material [ESM]).
Results
From a total of 5,221 patients with a diagnosis of diabetes,
24 patients met all the inclusion and exclusion criteria. Of
these 24 patients, 12 were willing to participate (ESM
Fig. 1). Five of the 12 non-obese patients with marked
insulin resistance had a lipodystrophic phenotype (Table 1).
Thus our selection criteria increased the likelihood of
identifying FPLD >400-fold, from 5/5,221 to 5/12.
The characteristics of the study participants are
described in Table 1. Participants S2 and S5 were
included in the study despite having a BMI >27 kg/m
2 at
the centre visit, as eligibility was based on data from the
patient’s medical records which, for both participants
showed a BMI ≤27 kg/m
2. Two of the patients with a
lipodystrophic phenotype (S11 and S12) had previously
been diagnosed with FPLD confirmed by mutations in
PPARG (R194W) [7]a n dLMNA (R482W) (E. S. Stroes,
unpublished observations). The third participant (S8) had
a history of systemic lupus erythematosus and chronic
corticosteroid use, which in itself may explain the
severe insulin resistance and abnormal skinfold thick-
ness measurement [8]. The fourth patient (S9) had
clinical features of FPLD, including lipodystrophy, but
no mutations in PPARG, LMNA or CIDEC. DNA analysis
of the fifth patient (S10) resulted in the identification of a
novel functional mutation in PPARG, establishing the
diagnosis of FPLD. This 61-year-old woman had a history
of type 2 diabetes since the age of 49 years, severe
hypertriglyceridemia with pancreatitis, hypertension and
cardiovascular disease (see ESM). Physical examination
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Diabetologia (2011) 54:1639–1644 1641showed a clear excess of subcutaneous fat on the face,
neck, trunk and abdomen with a lack of subcutaneous fat
on the extremities. Triceps skinfold thickness and upper
arm fat area were <5th percentile. MRI of tissue
confirmed these findings (ESM Fig. 2). No other
abnormalities related to FPLD were observed in this
patient, and there was no acanthosis nigricans or
hirsutism. Clinical features of lipodystrophy were also
found in the patient’s sister and son (see ESM).
S10 had a heterozygous A-to-G mutation in exon 5 of
the PPARG gene (Fig. 1a), resulting in a Y151C substitu-
tion in the PPARγ2 isoform. DNA sequence analysis of
family members of the index patient showed the same
mutation in the patient’s son, sister and nephew (Fig. 1b).
Tyrosine 151 is located in the DNA-binding domain
(DBD) of PPARγ and is completely conserved amongst
species and well conserved among nuclear receptors (ESM
Fig. 3).
Fig. 1 The FPLD-associated Y151C mutation reduces DNA binding,
and hence transcriptional activity of PPARγ. a The electropherogram
tracing shows both alleles from the proband (Y151C; PPARγ2
numbering) compared with corresponding genomic DNA sequence
from a healthy participant. The position of the mutation in the DBD is
indicated by the arrow. Nucleotide and amino-acid sequence is shown
below the electropherogram tracings. b Family pedigree. A diagonal
indicates ‘not genotyped’. Half-filled symbols indicate individuals
with the heterozygous Y151C mutation. Unaffected individuals are
indicated by unfilled symbols. The proband is indicated by an arrow. c
Global structure of the PPARγ–RXRα–DNA complex. The DBDs
and ligand-binding domains (LBDs) of PPARγ and RXRα are shown,
with the zinc ions in the PPARγ DBD. The square box indicates the
region magnified in d. d PPARγ–DNA interaction. Magnified view of
helices of PPARγ–DBD localised around the zinc ions, with Y151
indicated in stick format. Starting structure of PPARγ was adapted
from the Protein Data Bank entry 3DZY. Figures were generated using
PyMOL 0.99rc6 open source software (www.pymol.org). e Impaired
DNA binding of Y151C. In vitro translated RXRα or PPARγ2 (wild-
type [WT] or mutant) proteins were incubated with
32P-labelled probe
in absence or presence of 5× unlabelled probe (WT or mutant [mut])
as indicated. Protein–DNA complexes were separated from unbound
DNA on non-denaturing SDS-polyacrylamide gels and visualised by
autoradiography of dried gels. f The FPLD3-associated Y151C
mutation reduces the transcriptional activity of PPARγ2. U2OS cells
were transfected with expression vector encoding PPARγ2W To r
PPARγ2 Y151C respectively, and 3× peroxisome proliferator
response element (PPRE)-Tk-Luc reporter or a FABP4-Luc reporter.
Activation of the luciferase reporter, in the absence or presence of
1 μmol/l rosiglitazone, is expressed as fold induction over that with
empty vector (EV) in the absence of ligand, after normalisation for
Renilla luciferase activity. Results are averages of at least three
independent experiments assayed in duplicate ± SEM. g The FPLD3-
associated Y151C mutation fails to display dominant-negative
activity. U2OS cells were transfected with 3× PPRE-Tk-Luc reporter
and incubated with different concentrations of rosiglitazone (Rosi), as
indicated. WT PPARγ2 (black bars), WT PPARγ2 plus an equal
amount of WT PPARγ2 (light grey bars), WT PPARγ2 plus the
Y151C mutant (dark grey bars), or WT PPARγ2 plus the dominant-
negative L496A/E499A mutant (white bars), incubated with different
concentrations of rosiglitazone, as indicated. Reporter activities are
presented relative to the activity of WT PPARγ2 in the presence of
1 μmol/l rosiglitazone. Results are averages of at least three
independent experiments assayed in duplicate ± SEM
1642 Diabetologia (2011) 54:1639–1644CrystalstructurestudiesofthePPARγ–retinoidXreceptor,
α (RXRα) heterodimer bound to DNA indicate that Y151 is
in direct contact with the DNA backbone (Fig. 1c). In vitro
experiments showed the Y151C mutant to display reduced
DNA binding and transcriptional activity (Fig. 1d–e). As
shown in Fig. 1f,P P A R γ2 Y151C failed to display
dominant-negative activity.
Discussion
In the present study, we show an increase in the incidence
of FPLD in non-obese patients with type 2 diabetes mellitus
and marked insulin resistance. Characterisation of 12
participants fulfilling these criteria resulted in the identifi-
cation of five patients with lipodystrophic features. In three
patients the diagnosis of FPLD was supported by mutations
in PPARG or LMNA, with one patient harbouring a novel
heterozygous PPARG mutation (Y151C). These data indi-
cate that thorough evaluation for FPLD should be consid-
ered in non-obese patients with marked insulin resistance.
However, the numbers in our study may deviate from the
actual incidence of FPLD. First, the small number of
eligible patients willing to participate in the study may
have resulted in a positive ‘selection’ bias. Second, our
stringent inclusion criteria may have increased the false-
negative rate. The aim of the present study was to find
an effective method to select rare cases of FPLD from a
large group of individuals with the common type 2
diabetes mellitus. To effectively increase the chances of
identifying FPLD, we aimed to select patients with an
unusual phenotype, namely non-obese patients with
marked insulin resistance. Our inclusion criteria may,
however, have been too stringent as neither absence of
marked insulin resistance nor the presence of obesity
excludes the presence of FPLD.
It should be noted that lipodystrophy may be more
easily recognised in patients with increased BMI because
of the accentuated differences in subcutaneous fat in
extremities vs trunk when patients become obese. Thus,
although our selection criteria may serve as a guideline,
the presence of other typical features of FPLD, in any
patient, should still alert clinicians to the possibility of
lipodystrophy.
To date, 15 different FPLD-associated mutations in the
coding region of PPARG have been reported [9]. Here we
identified a novel heterozygous tyrosine-to-cysteine muta-
tion located in the region of the PPARG gene encoding the
DBD (Y151C). The mutation was shown to result in
reduced DNA binding and reduced transcriptional activity,
while direct dominant negative activity was absent. Tyro-
sine 151 is located in the DBD of PPARγ and is completely
conserved amongst species and within the nuclear receptor
superfamily. Interestingly, mutation of the analogous
position in the androgen receptor (Y571) to histidine or
cysteine has been associated with various forms of the
androgen insensitivity syndrome (Androgen Receptor Gene
Mutations Database; http://androgendb.mcgill.ca). Like the
PPARγ Y151C mutant reported in this study, the
androgen receptor Y571H mutant displayed impaired
DNA-binding capacity and hence reduced transcriptional
activity [10]. These findings underscore the importance of
this conserved tyrosine residue in DNA binding by nuclear
receptors.
In summary, our results indicate that careful assessment
of the clinical features of FPLD should be considered in
non-obese patients with marked insulin resistance, allowing
earlier therapeutic interventions.
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